We are proud to be a part of the ESMO BREAST CANCER Annual Congress 2026, May 06.-08., in Berlin, one of the world’s most influential oncology meetings organized by the European Society for Medical Oncology. Bringing together leading oncologists, translational researchers, pathologists, and innovators from across the globe, ESMO continues to shape the future of precision oncology and cancer care.

For MultiplexDX, ESMO 2026 marks another important milestone in our international journey. As an official conference partner, we are honored to showcase our latest research, scientific vision, and molecular diagnostic innovations directly at our exhibition booth, where we are experiencing tremendous interest and inspiring discussions with experts from the global oncology community.

Our team is excited to present the clinical potential of Multiplex8+, engage in meaningful scientific exchange, and strengthen collaborations that help advance more personalized treatment strategies for cancer patients worldwide. Moments like these remind us how far Slovak biotechnology and translational science can reach when driven by passion, perseverance, and purpose.

We are grateful to everyone who visited our booth and shared in the enthusiasm for the future of precision medicine.

Funded by the EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia under the project No. 09I01-03-V01-00003 and No. 09I03-03-V03-00101.

‍